PHILADELPHIA, Feb. 5, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery technologies, is proud to announce that the FDA has accepted their Membrane Proteome Array™ (MPA) ...
MPA on track to become the first NAM approved by the FDA for specificity testing PHILADELPHIA, Oct. 28, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and characterization, ...
PHILADELPHIA, Nov. 19, 2024 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and characterization, has been awarded $2.7 million by the NIH Commercialization Readiness Pilot (CRP) ...
An Integral Molecular scientist screens antibody drugs for specificity using the Membrane Proteome Array™, a high-throughput, cell-based, protein array technology. Integral Molecular, a leader in ...
Membrane proteins are key targets for therapeutic intervention using antibody biologics. Over 60% of FDA-approved drugs act on these proteins. Studying them is challenging because the proteins must be ...
The array, containing about 100 antibodies fixed on a nitrocellulose membrane, is incubated with the tissue to be stained. When the array is removed, the antibodies remain bound to proteins in the ...
Located at the cellular interface, membrane proteins play critical regulatory roles in the signaling between a cell and its interacting environment, making them popular and ideal drug targets.
Understanding the best ways to get a membrane protein to its destination in a cell is crucial, and the best method to make this happen is still unclear. Cell-free systems allow for interactions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results